Trial · NCT02466516
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 6 mg | TEAEs | 17 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 18 mg | TEAEs | 15 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 6 mg+SIM 125 mg | TEAEs | 9 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 18 mg+SIM 125 mg | TEAEs | 9 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SIM 125 mg | TEAEs | 7 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 6 mg | SAEs | 2 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 18 mg | SAEs | 2 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 6 mg+SIM 125 mg | SAEs | 0 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 18 mg+SIM 125 mg | SAEs | 1 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SIM 125 mg | SAEs | 0 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 6 mg | Any Grade ≥ 1 Laboratory Abnormality | 17 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 18 mg | Any Grade ≥ 1 Laboratory Abnormality | 21 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 6 mg+SIM 125 mg | Any Grade ≥ 1 Laboratory Abnormality | 9 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SEL 18 mg+SIM 125 mg | Any Grade ≥ 1 Laboratory Abnormality | 10 | Participants | |
| Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality | SIM 125 mg | Any Grade ≥ 1 Laboratory Abnormality | 8 | Participants | |
| Number of Participants Who Prematurely Discontinued Study Drug or Study Due to Adverse Events | SEL 6 mg | Discontinued Study Drug | 1 | Participants | |
| Number of Participants Who Prematurely Discontinued Study Drug or Study Due to Adverse Events | SEL 18 mg | Discontinued Study Drug | 2 | Participants | |
| Number of Participants Who Prematurely Discontinued Study Drug or Study Due to Adverse Events | SEL 6 mg+SIM 125 mg | Discontinued Study Drug | 0 | Participants | |
| Number of Participants Who Prematurely Discontinued Study Drug or Study Due to Adverse Events | SEL 18 mg+SIM 125 mg | Discontinued Study Drug | 0 | Participants | |
| Number of Participants Who Prematurely Discontinued Study Drug or Study Due to Adverse Events | SIM 125 mg | Discontinued Study Drug | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02466516/results